Constipation News and Research

Latest Constipation News and Research

Rhythm Awarded $1.35M From Michael J. Fox Foundation

...

10 Sep 2013

MJFF awards $1.35M to Rhythm for Phase 2 clinical trial of RM-131 for Parkinson's disease

Rhythm announced today that The Michael J. Fox Foundation for Parkinson's Research has awarded a $1.35 million research grant to Rhythm to help fund a Phase 2 clinical trial of RM-131, the company's novel ghrelin agonist, for the treatment of refractory constipation in patients with Parkinson's disease.

10 Sep 2013

Safety and health checklist to help kids avoid emergency room

With the school year underway, Children's Hospital Los Angeles experts have developed a safety and health checklist to help kids avoid the emergency room and develop productive extracurricular and learning activities to enhance the classroom experience. What do parents need to consider? Many symptoms of childhood conditions are often discovered in the classroom.

7 Sep 2013

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

OxyContin contains oxycodone, which is an opioid agonist. It is used for the management of moderate to severe pain when a constant opioid analgesic is needed for a prolonged period of time.

29 Aug 2013

Experts share tips on preventing ovarian cancer

Ovarian cancer is the fourth leading cause of death in American women. Approximately 22,000 women are diagnosed annually and 14,000 die from the disease. September is Ovarian Cancer Awareness month and Mount Sinai experts are sharing tips on prevention.

29 Aug 2013

Researchers develop new opioid drug for chronic pain

A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain.

29 Aug 2013

Review Article examines FMT methodology as effective treatment for C. difficile infection

Fecal microbiota transplantation has emerged as a highly effective treatment for recurrent Clostridium difficile infection, with very early experience suggesting that it may also play a role in treating other gastrointestinal and non-GI diseases.

23 Aug 2013

Patients with IBS-D treated with eluxadoline achieve better clinical response

Patients with diarrhea-predominant irritable bowel syndrome, or IBS-D, treated with eluxadoline achieved better clinical response and experienced more symptom improvement than those using placebo, according to a recent study in Gastroenterology, the official journal of the American Gastroenterological Association. Eluxadoline, which is currently in phase 3 trials, is under development as a potential treatment for IBS-D.

13 Aug 2013

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialisation of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the European Commission has authorised Lojuxta (lomitapide) hard capsules as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein apheresis in adult patients with homozygous familial hypercholesterolaemia.

3 Aug 2013

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Pain is defined by the sufferer’s experience. Pain may be severe because it is intense, frequent or sustained, and because it is distressing. The severity of pain is not simply due to what is going on in the joint, but is also affected by how the body processes the pain signals, and the context in which it is experienced.

31 Jul 2013

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer.

31 Jul 2013

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

Call it therapeutic poop, if you will, but the best hope yet for an effective treatment of childhood infections with the drug-resistant bacterium C. difficile may come straight from the gut, according to recent research.

30 Jul 2013

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Imprimis Pharmaceuticals, Inc., which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor.

23 Jul 2013

FDA approves Astellas' ASTAGRAF XL for prophylaxis of organ rejection in kidney transplant patients

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration has approved ASTAGRAF XLTM (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil and corticosteroids, with or without basiliximab induction.

20 Jul 2013

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Cubist Pharmaceuticals, Inc. today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Exposure to PFC may increase risk of mild hypothyroidism in women

Exposure to perfluorinated chemicals is linked to changes in thyroid function and may raise the risk of mild hypothyroidism in women, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

18 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

Protein complex may be an effective alternative to opioid pain medications

A drug targeting a protein complex containing two different types of opioid receptors may be an effective alternative to morphine and other opioid pain medications, without any of the side effects or risk of dependence, according to research led by the Icahn School of Medicine at Mount Sinai.

16 Jul 2013

Constipation News and Research

Latest Constipation News and Research

Rhythm Awarded $1.35M From Michael J. Fox Foundation

MJFF awards $1.35M to Rhythm for Phase 2 clinical trial of RM-131 for Parkinson's disease

Safety and health checklist to help kids avoid emergency room

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

Experts share tips on preventing ovarian cancer

Researchers develop new opioid drug for chronic pain

Review Article examines FMT methodology as effective treatment for C. difficile infection

Patients with IBS-D treated with eluxadoline achieve better clinical response

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

FDA approves Astellas' ASTAGRAF XL for prophylaxis of organ rejection in kidney transplant patients

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Exposure to PFC may increase risk of mild hypothyroidism in women

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Protein complex may be an effective alternative to opioid pain medications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Constipation News and Research

Latest Constipation News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in